Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL187542 | 0.91 | TDP1 (0.50) | TDP1ATMESPL1ALDH1A1HIF1A | |
| SCHEMBL29805163 | 0.91 | TDP1 (0.50) | TDP1ATMESPL1ALDH1A1HIF1A | |
| SCHEMBL12593915 | 0.89 | TDP1 (0.52) | TDP1ATMESPL1ALDH1A1HIF1A | |
| SCHEMBL21994357 | 0.88 | TDP1 (0.73) | TDP1ATMESPL1ALDH1A1HIF1A | |
| SCHEMBL2471756 | 0.87 | ALDH1A1 (0.47) | TDP1ATMALDH1A1HIF1ACYP1A2 | |
| SCHEMBL45486 | 0.84 | TDP1 (0.60) | TDP1ATMESPL1ALDH1A1HIF1A | |
| SCHEMBL397387 | 0.83 | ATM (0.50) | TDP1ATMESPL1ALDH1A1HIF1A | |
| SCHEMBL1828398 | 0.83 | ALDH1A1 (0.51) | TDP1ATMESPL1ALDH1A1HIF1A | |
| SCHEMBL29479185 | 0.83 | ALDH1A1 (0.51) | TDP1ATMESPL1ALDH1A1HIF1A | |
| SCHEMBL1770875 | 0.82 | CYP1A2 (0.52) | TDP1ATMESPL1ALDH1A1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112851493-B | Preparation method of 2,4, 5-trifluoro phenylacetic acid | 台州臻挚生物科技有限公司 | 2022-09-06 | — | — | CN | claimed |
| WO-2022099439-A1 | PREPARATION METHOD FOR 2,4,5-TRIFLUOROPHENYLACETIC ACID | 杭州臻挚生物科技有限公司 | 2022-05-19 | — | — | WO | claimed |
| CN-112851493-A | Preparation method of 2,4, 5-trifluorophenylacetic acid | 杭州臻挚生物科技有限公司 | 2021-05-28 | — | — | CN | claimed |
| US-20260115174-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | OCTANT INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12447153-B2 | HER2 mutation inhibitors | PFIZER INC. (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2025217213-A2 | COMPOSITIONS AND METHODS FOR TREATING RETINITIS PIGMENTOSA | OCTANT, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250304537-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2025-10-02 | — | — | US | disclosed |
| WO-2025101780-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | OCTANT, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| CN-119894872-A | Heteroarenes, pharmaceutical compositions containing heteroarenes, and methods of use thereof | 修复治疗公司 | 2025-04-25 | — | — | CN | disclosed |
| EP-4526293-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | Repare Therapeutics Inc. (CA) | 2025-03-26 | — | — | EP | disclosed |
| EP-3928836-B1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-09-18 | — | — | EP | disclosed |
| EP-2365752-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | Deciphera Pharmaceuticals, Llc (US) | 2011-09-21 | — | — | EP | disclosed |
| US-20100120806-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC | 2010-05-13 | — | — | US | disclosed |
| WO-2010051373-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2009110844-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF | ASTRAZENECA AB (SE) | 2009-09-11 | — | — | WO | disclosed |
| US-20090221642-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF-176 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221642-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF-176 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221642-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF-176 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-6096743-A | 1,2,3,4-tetrahydroquinoxalinedione derivative | YAMANOUCHI PHARMACEUTICALS CO., LTD. (JP) | 2000-08-01 | — | — | US | disclosed |
| EP-0784054-A1 | 1,2,3,4-TETRAHYDROQUINOXALINEDIONE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1997-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304537-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | CSNK1A1, CSNK1G1, CSNK2A1 | TDP1 533/4885ATM 261/4885ESPL1 396/4885 |
| US-20260115174-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | PDE6D, PDE6H, ADRA1D | TDP1 1657/4885ATM 4128/4885ESPL1 4678/4885 |
| US-20090221642-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF-176 | CHRM1, CHRM2, CHRM3 | TDP1 3176/4885ATM 1724/4885ESPL1 4047/4885 |
| US-20100120806-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | KIT, PDGFRA, PDGFRB | TDP1 2731/4885ATM 436/4885ESPL1 4196/4885 |
| US-12447153-B2 | HER2 mutation inhibitors | ERBB2, EGFR, ERBB3 | TDP1 3283/4885ATM 575/4885ESPL1 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.